Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IRMeizhong Jin, Prafulla C Gokhale, Andy Cooke, et al.
Bioorganic & Medicinal Chemistry Letters|March 1, 2011
Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2Andrew P Crew, Shripad V Bhagwat, Hanqing Dong, et al.
ACS Medicinal Chemistry Letters|April 16, 2021
Discovery of 2,4-1H-Imidazole Carboxamides as Potent and Selective TAK1 InhibitorsJohan J N Veerman, Yorik B Bruseker, Eddy Damen, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 2013
Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1Keith R Hornberger, Dan M Berger, Andrew P Crew, et al.
ACS Medicinal Chemistry Letters|February 14, 2012
Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of MalariaRichard W Heidebrecht, Carol Mulrooney, Christopher P Austin, et al.
Bioorganic & Medicinal Chemistry Letters|April 25, 2021
Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitorsVeronica Calvo, David Surguladze, An-Hu Li, et al.
The Journal of Clinical Investigation|June 18, 2024
Inhibition of the eukaryotic initiation factor-2α kinase PERK decreases risk of autoimmune diabetes in miceCharanya Muralidharan, Fei Huang, Jacob R Enriquez, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2013
Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinasesArno G Steinig, An-Hu Li, Jing Wang, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2024
Inhibition of the Eukaryotic Initiation Factor-2-α Kinase PERK Decreases Risk of Autoimmune Diabetes in MiceCharanya Muralidharan, Fei Huang, Jacob R Enriquez, et al.
Pageof 7